Lasolvan 30 mg – ambroxol tablets that thin mucus and make coughing easier. 20 tablets.
Ambroxol Hydrochloride
Lasolvan 30 mg
Pulmonology → mucolytic and antitussive agents → mucolytic and expectorant agents.
Active ingredient: ambroxol hydrochloride.
Each tablet contains 30 mg of ambroxol hydrochloride.
Excipients: lactose, copovidone, Aerosil, calcium stearate, crospovidone.
Tablets.
Ambroxol hydrochloride is a synthetic secretolytic and secretomotor agent. It stimulates mucus production in the bronchi, helps to thin it, and improves its elimination by increasing ciliated epithelial activity.
Ambroxol increases the concentration of surfactant in the lungs and helps prevent its breakdown. It has a mild antitussive effect. Ambroxol also has anti-inflammatory and antioxidant properties and stimulates local immunity.
Acute and chronic respiratory tract diseases accompanied by difficulty in eliminating viscous secretions:
It is also used for the prevention and treatment of complications following lung surgery, as well as for preparation for bronchoscopy and after the examination.
Consult a doctor before starting treatment.
The medicine should not be used for longer than the prescribed period without consulting a doctor.
A doctor should be consulted before using ambroxol hydrochloride during the second and third trimesters of pregnancy.
If the symptoms of the disease do not begin to disappear, or if the patient's health deteriorates or adverse reactions develop, treatment with ambroxol hydrochloride should be discontinued and a doctor should be consulted regarding further use of the medicine.
If the patient is taking other medicines, they should consult a doctor regarding the possibility of using this medicine.
Ambroxol hydrochloride increases the therapeutic efficacy of doxycycline, cefuroxime, and amoxicillin. The medicine increases the concentration of rifampicin in the lungs.
This medicine may be used together with cardiac glycosides and diuretics. Combination of ambroxol hydrochloride with theophylline is considered therapeutically appropriate.
Concomitant use of ambroxol hydrochloride with antitussive medicines that inhibit the elimination of sputum is not recommended.
A doctor should be consulted before and during treatment.
The medicine is secreted into breast milk; however, the use of ambroxol hydrochloride at therapeutic doses does not cause adverse effects in infants.
Adults and children over 12 years of age take 1 tablet twice daily, and if necessary, up to 3 times daily.
During exacerbations of chronic diseases, the single dose may be increased to 60 mg (2 tablets) twice daily.
Children aged 5–12 years are usually prescribed 15 mg (1/2 tablet) 2–3 times daily, while children aged 2–5 years are prescribed 7.5 mg (1/4 tablet) 2–3 times daily.
The medicine is taken during or after meals with a small amount of water.
The therapeutic dose in children is 1.2–1.6 mg/kg per day divided into 2–3 doses.
The course of treatment is 4–14 days.
No cases of overdose have been reported; however, digestive disturbances, discomfort or pain in the epigastric region, a feeling of stomach fullness, nausea, and vomiting may occur.
In cases of overdose, treatment with the medicine should be discontinued and a doctor should be consulted.
Treatment: symptomatic.
